Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303).
Wanebo HJ, Lee J, Burtness BA, Ridge JA, Ghebremichael M, Spencer SA, Psyrri D, Pectasides E, Rimm D, Rosen FR, Hancock MR, Tolba KA, Forastiere AA. Wanebo HJ, et al. Among authors: pectasides e. Ann Oncol. 2014 Oct;25(10):2036-2041. doi: 10.1093/annonc/mdu248. Epub 2014 Jul 9. Ann Oncol. 2014. PMID: 25009013 Free PMC article. Clinical Trial.
Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype.
Rampias T, Pectasides E, Prasad M, Sasaki C, Gouveris P, Dimou A, Kountourakis P, Perisanidis C, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A. Rampias T, et al. Among authors: pectasides e. Ann Oncol. 2013 Aug;24(8):2124-31. doi: 10.1093/annonc/mdt013. Epub 2013 Feb 13. Ann Oncol. 2013. PMID: 23406730 Free article.
Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.
Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Psyrri A, et al. Among authors: pectasides e. Clin Cancer Res. 2014 Jun 1;20(11):3023-32. doi: 10.1158/1078-0432.CCR-14-0113. Epub 2014 Apr 3. Clin Cancer Res. 2014. PMID: 24700741 Free PMC article. Clinical Trial.
Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis.
Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, Grandis J, Psyrri A. Pectasides E, et al. Clin Cancer Res. 2010 Apr 15;16(8):2427-34. doi: 10.1158/1078-0432.CCR-09-2658. Epub 2010 Apr 6. Clin Cancer Res. 2010. PMID: 20371693 Free PMC article.
Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.
Kim ST, Banks KC, Pectasides E, Kim SY, Kim K, Lanman RB, Talasaz A, An J, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Park SH, Park JO, Park YS, Lim HY, Kim NKD, Park W, Lee H, Bass AJ, Kim K, Kang WK, Lee J. Kim ST, et al. Among authors: pectasides e. Ann Oncol. 2018 Apr 1;29(4):1037-1048. doi: 10.1093/annonc/mdy034. Ann Oncol. 2018. PMID: 29409051 Free PMC article. Clinical Trial.
Carboplatin and paclitaxel in metastatic or recurrent cervical cancer.
Pectasides D, Fountzilas G, Papaxoinis G, Pectasides E, Xiros N, Sykiotis C, Koumarianou A, Psyrri A, Panayiotides J, Economopoulos T. Pectasides D, et al. Among authors: pectasides e. Int J Gynecol Cancer. 2009 May;19(4):777-81. doi: 10.1111/IGC.0b013e3181a40a8b. Int J Gynecol Cancer. 2009. PMID: 19509587
58 results